{
    "clinical_study": {
        "@rank": "33573", 
        "arm_group": [
            {
                "arm_group_label": "Blisibimod", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the effect of blisibimod plus standard of care\n      versus placebo plus standard of care alone on the proportion of subjects achieving\n      improvement in renal disease parameters."
        }, 
        "brief_title": "BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy", 
        "completion_date": {
            "#text": "October 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "IgA Nephropathy", 
        "condition_browse": {
            "mesh_term": [
                "Glomerulonephritis, IGA", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or older.\n\n          -  Biopsy-proven IgA nephropathy\n\n          -  Proteinuria \u2265 2g/24hr or equivalent\n\n          -  Receiving physician-directed optimized standard of care that includes ACEI and/or\n             ARB.\n\n          -  Estimated glomerular filtration rate (eGFR) >40mL/min/1.73m2\n\n        Exclusion Criteria:\n\n          -  Clinical or histologic evidence of non-IgA-related glomerulonephritis\n\n          -  IgA nephropathy with greater than 50% glomerulosclerosis or cortical scarring\n\n          -  Meets eGFR criteria\n\n          -  Malignancy within past 5 years\n\n          -  Known to be positive for HIV and/or positive at the screening visit for hepatitis B,\n             or hepatitis C\n\n          -  Liver disease\n\n          -  Neutropenia\n\n          -  Active infection requiring hospitalization or treatment with parenteral antibiotics\n             within the past 60 days or history of repeated herpetic viral infections\n\n          -  History of active tuberculosis or a history of tuberculosis infection\n\n          -  Pregnant or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052219", 
            "org_study_id": "AN-IGN3331"
        }, 
        "intervention": [
            {
                "arm_group_label": "Blisibimod", 
                "description": "Blisibimod administered subcutaneously", 
                "intervention_name": "Blisibimod", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo administered subcutaneously", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Blisibimod", 
            "IgA nephropathy", 
            "BAFF", 
            "BLyS"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The proportion of subjects to achieve the proteinuria threshold", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "The proportion of subjects who progress to end-stage renal disease", 
                "safety_issue": "No", 
                "time_frame": "approximately 5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052219"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in serum immunoglobulins IgA, IgG and IgM, plasma cells and B cell subsets", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Change from baseline in serum creatinine", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Change from baseline in eGFR", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "The proportion of subjects requiring the addition of corticosteroid or other therapy", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }
        ], 
        "source": "Anthera Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anthera Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}